A clinical trial on the efficacy and safety in uncontrolled moderate–severe asthma of tozorakimab (MEDI3506) [198] (a human IgG1 anti-IL-33 antibody that inhibits IL-33 signaling through ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunctions) (FRONTIER-3) (NCT04570657) [199] has recently been completed. This evidence concerns the gene IL33 and asthma.